Expert Interview
A second look at Verona Pharma's ensifentrine for the treatment of chronic obstructive pulmonary disease before the PDUFA on June 26th
Ticker(s): VRNAInstitution: Velocity Clinical Research (Grosshansdorf, Germany)
- Medical Director and Principal Investigator at VCR and previously co-led the Pulmonary Research Institute at the LungeClinic Grosshansdorf (PRI) since 2007.
- Treats over 1000 patients with COPD in clinic, as outpatients, and in clinical research.
- Clinical and research interest in COPD, bronchial asthma, bronchiectasis and pulmonary fibrosis, sarcoidosis, lymphangioleiomyomatosis, and pulmonary hypertension in fibrosing lung diseases, having conducted over 300 studies, as well as contributed to more than 250 publications and over 300 conferences.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
